<DOC>
	<DOCNO>NCT00184600</DOCNO>
	<brief_summary>This trial conduct Europe . The aim research study compare efficacy ( reduction HbA1c blood glucose level ) insulin detemir , insulin aspart biphasic insulin aspart 30 , add current OAD ( oral anti-diabetic drug ) treatment subject type 2 diabetes verify safety use ( number severity episodes hypoglycaemia , body weight side effect ) .</brief_summary>
	<brief_title>Comparison Insulin Detemir , Insulin Aspart Biphasic Insulin Aspart 30 With OAD Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Insulin naive On OAD treatment least 4 month metformin , sulphonylurea combination Body Mass Index ( BMI ) equal 40.0 kg/m2 HbA1c ( glycosylated haemoglobin ) : 7.0 % 10 % ( inclusive ) Proliferative retinopathy Recurrent major hypoglycaemia Cardial problem Uncontrolled hypertension Impaired hepatic renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>